Home/Pipeline/Biosimilar Portfolio (e.g., Filgrastim)

Biosimilar Portfolio (e.g., Filgrastim)

Chemotherapy-induced Neutropenia

CommercialMarketed

Key Facts

Indication

Chemotherapy-induced Neutropenia

Phase

Commercial

Status

Marketed

Company

Emcure Pharmaceuticals

About Emcure Pharmaceuticals

A major Indian pharmaceutical company developing and commercializing a broad portfolio of branded generics, biosimilars, and novel formulations across multiple therapeutic areas.

View full company profile

Therapeutic Areas

Women's Health Cardiovascular Anti-infectives Critical Care Gastroenterology Oncology Supportive Care

Other Chemotherapy-induced Neutropenia Drugs

Drug	Company	Phase	Status
BBT-015	Bolder Biotechnology	Preclinical	Active
Bmab 1100 (Pegfilgrastim biosimilar)	Biocon	Approved	Commercial
Ziextenzo (pegfilgrastim)	Sandoz Group	Marketed	Commercial
Biosimilar Pegfilgrastim	Viatris	Launched	Marketed (ex-US)
UDENYCA (pegfilgrastim-cbqv)	Coherus BioSciences	Approved	Commercial
ROLVEDON	Assertio Holdings	Approved	Marketed